RecruitMe Clinical Trial

A Randomized, Double-Blind, Placebo-Controlled Trial of Adjunctive BHV-4157 in Obsessive-Compulsive Disorder
A Randomized, Double-Blind, Placebo-Controlled Trial of Troriluzole for OCD
Sponsor:Biohaven Pharmaceutical Holding Company LTD.
Enrolling:Male and Female Patients
Age Range:Between 18 and 65 years old
IRB Number:7564
U.S. Government ID:NCT03299166
Contact: Rachel Middleton: 646-774-8138 / Rachel.Middleton@nyspi.columbia.edu
Additional Study Information:

For this study, eligible participants will be asked questions about their symptoms and complete a medical evaluation. You will receive a medication, and be monitored by medical professionals. You will also be asked to complete questionnaires. The purpose of this study is to assess to evaluate a medication for the treatment of OCD. Specifically, the goal is to learn the difference in how this medication works compared to placebo (or sugar pill with no medication; to evaluate how safe and how well tolerated it is when administered; and to evaluate how it works compared to placebo using scales that assess other aspects of your health that may be affected by OCD. For more information about participating, please call Rachel Middleton at (646) 774-8138 or email her at Rachel.Middleton@nyspi.columbia.edu.

Do You Qualify?
Are you between the ages of 18 - 65?YesNo
Do you have bothersome OCD symptoms?YesNo
Are you currently taking an SSRI, SNRI, or antidepressant?YesNo
Are you interested in trying a new medication?YesNo
Submit
Cancel
Investigator
Helen Simpson, MD, PhD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Rachel Middleton
Email: Rachel.Middleton@nyspi.columbia.edu
Phone: 646-774-8138